Welcome to our dedicated page for CATALENT news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on CATALENT stock.
Catalent, Inc. (symbol: CTLT) is a leading contract development and manufacturing organization (CDMO) that plays a crucial role in the global pharmaceutical and biotechnology industries. With over 80 years of experience, Catalent specializes in providing a comprehensive range of development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company operates under four main segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
At Catalent, innovation and expertise are at the core of their operations. The company is dedicated to accelerating the development and delivery of new treatments by leveraging its advanced technologies and extensive industry knowledge. Catalent's services span the entire lifecycle of a product, from initial drug development and clinical trials to commercial manufacturing and packaging. This end-to-end approach allows them to support pharmaceutical customers with long-term supply agreements and partnerships.
One of Catalent's key strengths lies in its global presence. The company operates over 50 state-of-the-art facilities across four continents, ensuring that it can meet the diverse needs of its clients worldwide. By providing tailored solutions and maintaining high standards of quality and reliability, Catalent has established itself as a trusted partner for many of the world's leading pharmaceutical companies.
Catalent's commitment to innovation is evident through its focus on drug delivery technologies. As a world leader in this field, the company has a proven track record of enhancing bioavailability, solubility, and permeability of drug compounds. These advancements not only improve the efficacy of treatments but also enhance patient compliance and outcomes. Catalent's expertise in developing more effective and convenient drug delivery methods has made a significant impact on the healthcare industry.
Financially, Catalent remains robust, with consistent revenue generation driven by its long-term contracts and diverse service offerings. The company's ability to adapt to market demands and invest in cutting-edge technologies has positioned it for sustained growth. Recent achievements include the expansion of their biologics capabilities and strategic collaborations with key industry players to advance cell and gene therapies.
In conclusion, Catalent, Inc. stands as a pivotal entity in the pharmaceutical and biotechnology sectors. Through their extensive range of services, global reach, and unwavering commitment to innovation, they continue to drive faster, more efficient development timelines and deliver superior manufacturing and packaging solutions. For investors and stakeholders, Catalent represents a vital player in the advancement of modern medicine and healthcare.
Exelixis (Nasdaq: EXEL) has entered a new licensing agreement with Catalent (NYSE: CTLT) for three oncology programs aimed at developing antibody-drug conjugates (ADCs) for various solid tumors. Exelixis will pay $30 million upfront for rights to the biologics programs and will fund the development until candidate selection. This collaboration enhances Exelixis’ biologics pipeline, targeting cancers including bladder, breast, and ovarian. Catalent's SMARTag technology will support the development, potentially improving treatment options for cancer patients.
Catalent reported Q1'23 net revenue of $1.02 billion, unchanged from last year but up 4% in constant currency. Organic net revenue dipped 1%. Adjusted EBITDA fell 26% to $187 million. Results were negatively impacted by $54 million due to contract timing but are expected to be recognized in Q2'23. The acquisition of Metrics Contract Services for $475 million was finalized in October 2022. Updated guidance for FY'23 projects net revenue between $4,625 million and $4,875 million with Adjusted EBITDA of $1,220 million to $1,300 million.
Catalent, Inc. (NYSE: CTLT) will announce its financial results for Q1 FY2023 on November 1, 2022, before market open. The results cover the period ending September 30, 2022. Following the release, a management webcast is scheduled for 8:15 a.m. ET on the same day to discuss the results. A supplemental presentation will be available on the company's website, and the webcast replay will last for 90 days. Catalent, a leader in drug development and manufacturing, generated nearly $5 billion in revenue in FY2022.
Catalent, Inc. (NYSE: CTLT) is set to participate in two investor conferences: the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 at 11:45 a.m. ET, and the Baird’s 2022 Global Healthcare Conference on September 14 at 10:50 a.m. ET. A live webcast of these presentations will be available on their investor website, with replays following the events. Catalent is a global leader in optimizing product development and supply for pharma, biotech, and consumer health, generating nearly $5 billion in revenue in FY2022.
Catalent, Inc. (CTLT) reported a robust Q4'22 net revenue of $1.31 billion, a 10% increase year-over-year, with a 15% growth in constant currency. For FY'22, total net revenue reached $4.83 billion, up 21% as reported. Q4'22 net earnings soared to $188 million, translating to $1.04 per share. Adjusted EBITDA for Q4'22 was $384 million, marking a 10% increase, while FY'22 Adjusted EBITDA hit $1.29 billion, a 26% rise. FY'23 guidance estimates net revenue between $4,975 million and $5,225 million.
Catalent has announced its acquisition of Metrics Contract Services for $475 million from Mayne Pharma, aiming to enhance its capabilities in oral solid formulation development and manufacturing. The acquisition includes Metrics' 333,000 square-foot facility in Greenville, North Carolina, featuring significant investment in upgrades and the capacity to produce over one billion oral solid dose units annually. This strategic move will allow Catalent to meet growing customer demands in the biopharma sector.
Catalent (NYSE:CTLT) will release its financial results for the fourth quarter of fiscal year 2022, ending June 30, 2022, on August 29, 2022, before market opening. A webcast discussing these results will follow at 8:15 AM ET on the same day. Catalent is recognized as a leader in advanced delivery technologies and clinical supply solutions for pharmaceuticals and consumer health products, generating approximately $4 billion in revenue during the 2021 fiscal year and supporting over 1,000 partner programs annually.
Catalent, Inc. (NYSE: CTLT) has restructured its operations from four reporting segments to two as of July 1. The new segments focus on Biologics and Pharma and Consumer Health, with the latter consolidating multiple previous segments to enhance service integration. This change aims to better align with customer needs and industry trends, as stated by CEO Alessandro Maselli. Leadership changes include new roles for Jonathan Arnold and Steven Fasman, while Karen Flynn has announced her retirement.
Quanterix Corporation (NASDAQ: QTRX) has appointed Karen A. Flynn, Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), to its Board of Directors effective June 6, 2022. With over 35 years in the pharmaceutical services industry, Flynn's experience includes leadership roles at Catalent and West Pharmaceutical Services. Her expertise in commercial strategy and operations is expected to drive Quanterix's growth and enhance its impact in healthcare research and diagnostics.
FAQ
What is the current stock price of CATALENT (CTLT)?
What is the market cap of CATALENT (CTLT)?
What is Catalent, Inc.'s core business?
How many facilities does Catalent operate?
What segments does Catalent operate under?
What is Catalent known for in drug delivery technologies?
Who are Catalent's primary customers?
What recent achievements has Catalent made?
How does Catalent support drug development?
What distinguishes Catalent in the pharmaceutical industry?
What is the significance of Catalent's global presence?
How does Catalent ensure the quality of their services?
